StockIQpro
NASDAQ:RGEN

Repligen Corp.

Repligen Corp.'s revenue grew 16.4% in fiscal 2025 to $738.3M while operating margin rose to 7.5%. Free cash flow was $93.9M, 12.7% of revenue, and the diluted share count rose 1.1%.Summary generated from Repligen Corp.'s SEC filings. Latest annual report filed Feb 26, 2026.

Revenue (FY25)$738.3M
Revenue growth+16.4%
Revenue, 5-yr CAGR+15.0%
Gross margin52.3%
Operating margin7.5%
Net margin6.6%
ROIC2.3%
Return on equity2.4%
Debt / equity0.26
Free cash flow$93.9M
FCF margin12.7%
Share count change+1.1%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue671802632634738
Operating income16722548−3555
Net income12818636−2649
Free cash flow52877815094

Recent filings

From SEC EDGAR

Peers

Biological products, (no diagnostic substances)